by an ester linkage, or $-O-X-(R_5)_m$; m being two or three and X being selected from the group consisting of C, P or S; wherein: $R_5$ is a member independently selected from the group consisting of:

hydrogen atom**, wherein no more than two $R_5$s are hydrogen**;

hydroxyl group;

=O;

**dimethylamino;**

substituted or unsubstituted $C_{(3-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxyl, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ acetoxyalkyl, $C_{(1-10)}$ carboxyalkyl, $C_{(1-10)}$ hydroxyalkyl, or substituted $C_{(1-2)}$ alkyl group;

$-OR_6$, $R_6$ being a substituted or unsubstituted $C_{(1-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, or $C_{(1-10)}$ oxoalkyl; [and]

substituted or unsubstituted [carbocyclic or] heterocylic group having one or two rings, each ring containing from four to seven atoms **, wherein the heteroatom(s) of said heterocyclic group is 1 or 2 nitrogens; and**

**substituted or unsubstituted carbocyclic group, having one or two rings, each ring containing from four to seven atoms, wherein the substituents of said substituted carbocyclic group are selected from the group consisting of amino, $C_{(2-6)}$ alkenyl, $C_{(1-6)}$ alkyl, $C_{(1-6)}$ alkoxyl, $C_{(1-6)}$ hydroxyalkyl, hydroxyl, $C_{(1-6)}$ oxoalkyl, azido, carboxy, cyano, $C_{(2-6)}$ mono- or di-haloalkyl, isocyano, isothiocyano, phospho, phosphono, sulfonato, imino, thioalkoxyl, a chlorine atom, a bromine atom, a fluorine atom and an oxygen atom**.

6. (Twice Amended) The compound of claim 1, wherein substituents for the substituted $C_{(1-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxyl, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ acetoxyalkyl[, cyclic] or heterocylic groups are selected from the group consisting of amino, $C_{(2-6)}$ alkenyl, $C_{(1-6)}$ alkyl, $C_{(1-6)}$ alkoxyl, [primary, secondary or tertiary] $C_{(1-6)}$ hydroxyalkyl, $C_{(1-6)}$ oxoalkyl, azido, [carbonyl, carboxyalkyl] **carboxy**, cyano, $C_{(1-6)}$ haloalkyl,

isocyano, isothiocyano, [alkylphosphate] **phospho**, [alkylphosphonate] **phosphono**, [alkylsulfonate] **sulfonato**, [sulfonyl, sulfoxyl,] imino, [thiocarbonyl,] thioalkoxyl or a chlorine, bromine fluorine and oxygen atom.

9. (Twice Amended) The compound of claim 1, wherein one or two, nonadjacent carbon atoms of [the $R_1$ or] $R_2$[, other than formula II,] are replaced with oxygen atoms.

10. (Twice Amended) The compound of claim 1, wherein the cyclic or heterocyclic is selected from the group consisting of benzyl, phenyl, biphenyl, cyclohexyl, cyclohexenyl, cyclopentyl, nicotinyl, cyclopentenyl, cyclopentanedionyl, napthlalenyl, phenolyl, quinonyl, [cyclopropyl,] cyclobutyl, cycloheptyl, cycloheptenyl, indanyl, indenyl, decalinyl, resorcinolyl, tetralinyl, α-tetralonyl, 1-indanonyl, cyclohexanedionyl, cyclopentanedionyl, dimethylxanthinyl, methylxanthinyl, phthalimidyl, homophthalimidyl, [methylbenzoyleneuryl] **methylbenzoyleneurea-moiety**, quinazolinonyl, octylcarboxamidophenyl, [methylbenzamido] **N-methylbenzamido**, [methyldioxotetrahydropteridyl] **1-methyl-2,4-dioxotetrahydropteridyl**, glutarimidyl, piperidonyl, succinimidyl, dimethoxyphenyl, methyldihydrouracilyl, methyluracilyl, methylthyminyl, piperidinyl, dihydroxybenzenyl, methylpurinyl, methylxanthinyl and dimethylxanthinyl.

12. (Amended) The compound of claim 11, wherein the other $R_5$, other than =O, is selected from the group consisting of trimethoxy-substituted phenyl, [phenolyl] **hydroxyphenyl** and [benzamino] **aminophenyl**.

14. (Amended) The compound of claim 1, wherein the compound is selected from :



15. (Twice Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound having the following formula I:



I

wherein [one of] $R_1$ has the formula II:



II

$R_1$ or $R_2$, which is other than formula II, and $R_3$ are independently $C_{(1-12)}$ alkyl, optionally, one or [more] **two nonadjacent** carbon atoms of the $C_{(1-12)}$ alkyl being replaced by an oxygen atom; and wherein:

C* is a chiral carbon atom;

n is an integer from four to eight;

$R_4$ is a naturally occurring amino acid or carbohydrate **moiety** attached **by an oxygen atom** to the chiral carbon atom C* by an ester linkage, or $-O-X-(R_5)_m$; m being two or three and X being selected from the group consisting of C, P or S; wherein:

$R_5$ is a member independently selected from the group consisting of:

hydrogen atom**, wherein no more than two $R_5$s are hydrogen**;

hydroxyl group;

=O;

**dimethylamino;**

substituted or unsubstituted $C_{(1-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxyl, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ acetoxyalkyl, $C_{(1-10)}$ carboxyalkyl or $C_{(1-10)}$ hydroxyalkyl group;

$-OR_6$, $R_6$ being a substituted or unsubstituted $C_{(1-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, or $C_{(1-10)}$ oxoalkyl; [and]

substituted or unsubstituted [carbocyclic or] heterocylic group having one or two rings, each ring containing from four to seven atoms **, wherein the heteroatom(s) of said heterocyclic group is 1 or 2 nitrogens; and**

**substituted or unsubstituted carbocyclic group, having on or two rings, each ring containing from four to s v n atoms, wher in th substituents of said substituted**

**carbocyclic group ar select d from th group consisting of amino, $C_{(2-6)}$ alkenyl, $C_{(1-6)}$ alkyl, $C_{(1-6)}$ alkoxyl, $C_{(1-6)}$ hydroxyalkyl, hydroxyl, $C_{(1-6)}$ oxoalkyl, azido, carboxy, cyano, $C_{(2-6)}$ mono- or di-haloalkyl, isocyano, isothiocyano, phospho, phosphono, sulfonato, imino, thioalkoxyl, a chlorine atom, a bromine atom, a fluorine atom and an oxygen atom**.

20. (Amended) A compound of formula I:



I

wherein [one of] $R_1$ or $R_2$ has the formula II:



II

$R_1$ or $R_2$, which is other than formula II, and $R_3$ are independently $C_{(1-12)}$ alkyl, optionally, one or [more] **two nonadjacent** carbon atoms of the $C_{(1-12)}$ alkyl being replaced by an oxygen atom; and wherein:

C* is a chiral carbon atom;

n is an integer from five to eight;

$R_4$ is a naturally occurring amino acid or carbohydrate **moiety** attached **by an oxygen atom** to the chiral carbon atom C* by an ester linkage, or $-O-X-(R_5)_m$; m being two or three and X being selected from the group consisting of C, P or S; wherein:

$R_5$ is a member independently selected from the group consisting of:

hydrogen atom**, wherein no more than two $R_5$s are hydrogen**;

hydroxyl group;

=O;

**dim thylamino;**

substituted or unsubstituted $C_{(1-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxyl, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ acetoxyalkyl, $C_{(1-10)}$ carboxyalkyl or $C_{(1-10)}$ hydroxyalkyl group;

$-OR_6$, $R_6$ being a substituted or unsubstituted $C_{(1-10)}$ alkyl, $C_{(2-10)}$ alkenyl, $C_{(2-10)}$ alkynyl, or $C_{(1-10)}$ oxoalkyl; [and]

substituted or unsubstituted [carbocyclic or] heterocylic group having one or two rings, each ring containing from four to seven atoms **, wherein the heteroatom(s) of said heterocyclic group is 1 or 2 nitrogens; and**

**substituted or unsubstituted carbocyclic group, having one or two rings, each ring containing from four to seven atoms, wherein the substituents of said substituted carbocyclic group are selected from the group consisting of amino, $C_{(2-6)}$ alkenyl, $C_{(1-6)}$ alkyl, $C_{(1-6)}$ alkoxyl, $C_{(1-6)}$ hydroxyalkyl, hydroxyl, $C_{(1-6)}$ oxoalkyl, azido, carboxy, cyano, $C_{(2-6)}$ mono- or di-haloalkyl, isocyano, isothiocyano, phospho, phosphono, sulfonato, imino, thioalkoxyl, a chlorine atom, a bromine atom, a fluorine atom and an oxygen atom**.

## REMARKS

### I. Introduction

Applicants hereby request reconsideration of the present application in view of the foregoing amendments and the following remarks. In light of the Request for Extension of Time, filed concurrently herewith, Applicants respectfully request acknowledgement of the current pendency of the application in caption. Claims 1, 6, 9, 12, 14 and 20 have been amended. No claims have been cancelled or added. Thus, upon entry of the foregoing amendments, claims 1-7 and 9-20 will remain pending. Support for all amendments is found in either the claims themselves or in the specification at pages 6-8 and, in